Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

All Drugs and Chemicals

Amino Acids

Bilirubin

N-Methylaspartate

Aspartic Acid

Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase \[AST\] less than or equal to \[\<=\] Upper limit of normal \[ULN\]) will be administered with Belantamab mafodotin

Participants with moderate hepatic impairment (Serum bilirubin greater than \>1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin

Participants with severe hepatic impairment (Serum bilirubin \>3 times ULN and any AST) will be administered with Belantamab mafodotin

Belantamab mafodotin will be administered

Belantamab mafodotin

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

Krisstina Gowin

Eli Gabayan

Jason Eli Tache

Seema Singhal

Shaker R Dakhil

Mehmet Hakan Kocoglu

David Vesole

Kathleen Dorritie

Mary Kuntz Crow

Michael A Thompson

Sosana Delimpasi

Meletios Athanasios Dimopoulos

Sung-Hyun Kim

Ho-Jin Shin

Sang Kyun Sohn

Je-Jung Lee

Jae Hoon Lee

Ho-Young Yhim

Youngil Koh

Chang Ki Min

Jin Seok Kim

Yoon Seok Choi

GSK Clinical Trials

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)

IPD for this study will be made available via the Clinical Study Data Request site.

GlaxoSmithKline

Spots Global Cancer Trial Database for dreamm 13

Every month we try and update this database with for dreamm 13 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dreamm 13

Every month we try and update this database with for dreamm 13 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dreamm 13 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.